Clinical Trial Services Agreement Sample Contracts

Vascular Biogenics Ltd. – Clinical Trial Services Agreement (March 15th, 2018)

This Clinical Trial Services Agreement ("Agreement") is between Vascular Biogenics Ltd. ("Sponsor"), and the GOG Foundation, Inc. ("GOG"), a not-for-profit corporation organized under the laws of the District of Columbia, to conduct the Clinical Trial according to the protocol attached as Exhibit A ("Protocol") and incorporated by reference into this Agreement.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 8 to Work Statement Nb-1 (February 25th, 2016)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 8 to Work Statement NB-1 (Amendment No. 8) effective as of August 15, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 8 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 5 to Work Statement Nb-3 (February 25th, 2016)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 5 to Work Statement NB-3 (Amendment No. 5) effective as of January 15, 2016 (Amendment Date). Capitalized terms used in this Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 4 to Work Statement Nb-3 (February 25th, 2016)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 4 to Work Statement NB-3 (Amendment No. 4) effective as of October 21, 2015 (Amendment Date). Capitalized terms used in this Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 3 (August 6th, 2015)

The parties wish to enter into this Amendment No. 3 effective as of July 8, 2015 (Amendment Date). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in this Agreement.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 2 to Work Statement Nb-3 (May 6th, 2015)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 2 to Work Statement NB-3 (Amendment No. 2) effective as of March 23, 2015 (Amendment Date). Capitalized terms used in this Amendment No. 2 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 9 to Work Statement Nb-1 (May 6th, 2015)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 9 to Work Statement NB-1 (Amendment No. 9) effective as of 12 March, 2015 (Amendment Date). Capitalized terms used in this Amendment No. 9 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 7 to Work Statement Nb-1 (August 12th, 2014)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 7 to Work Statement NB-1 (Amendment No. 7) effective as of July 22, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 7 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 6 to Work Statement Nb-1 (August 12th, 2014)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 6 to Work Statement NB-1 (Amendment No. 6) effective as of July 22, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 6 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 5 to Work Statement Nb-1 (May 20th, 2014)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 5 to Work Statement NB-1 (Amendment No. 5) effective as of May 19, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 5 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 4 to Work Statement Nb-1 (April 1st, 2014)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 4 to Work Statement NB-1 (Amendment No. 4) effective as of March 28, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 4 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 1 to Work Statement Nb-3 (March 10th, 2014)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-3 (Amendment No. 1) effective as of February 28, 2014 (Amendment Date). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-3.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 3 to Work Statement Nb-1 (November 14th, 2013)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 3 to Work Statement NB-1 (Amendment No. 3) effective as of November 6, 2013 (Amendment Date). Capitalized terms used in this Amendment No. 3 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 1 to Work Statement Nb-2 (November 14th, 2013)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-2 (Amendment No. 1) effective as of November 6, 2013 (Amendment Date). Capitalized terms used in this Amendment No. 1 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-2.

Radius Health, Inc. – Clinical Trial Services Agreement Amendment No. 2 to Work Statement Nb-1 (June 22nd, 2012)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 2 to Work Statement NB-1 (Amendment No. 2) effective as of June 18, 2012 (Amendment Date). Capitalized terms used in this Amendment No. 2 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Confidential Treatment Requested Under 17 C.F.R. SSSS 200.80(b)(4) and 240.24b-2 CLINICAL TRIAL SERVICES AGREEMENT AMENDMENT NO. 1 TO WORK STATEMENT NB-1 (December 15th, 2011)

Pursuant to Section 2.3, 2.11 and 11.7 of the Agreement, the parties wish to enter into this Amendment No. 1 to Work Statement NB-1 (Amendment No. 1) effective as of December 9, 2011 (Amendment Date). Capitalized terms used in this Amendment No. 1 and not defined herein are used with the meanings ascribed to them in the Agreement and Work Statement NB-1.

Radius Health, Inc. – Clinical Trial Services Agreement* (October 24th, 2011)

This Clinical Trial Services Agreement (this Agreement) is entered into as of March 29, 2011 (Effective Date) by and between RADIUS HEALTH, INC., a Delaware corporation (Radius) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (NB) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.

CLINICAL TRIAL SERVICES AGREEMENT This Agreement Is Effective October 4, 2011 ("Effective Date") by and Between: Harvard Clinical Research Institute, Inc. ("HCRI") (October 11th, 2011)

WHEREAS, InspireMD ("Sponsor") desires to engage HCRI for the purpose of providing Clinical Trial Services, as defined in Exhibit A to this Agreement, which will serve as the Scope of Work and budget for the Agreement, for the protocol for the "MGuard Stent System Clinical Trial in Patients with Acute Myocardial Infarction" Study, which shall be developed by HCRI under a separate consulting agreement, with such Protocol being incorporated by reference; and

Radius Health, Inc. – Clinical Trial Services Agreement* (September 30th, 2011)

This Clinical Trial Services Agreement (this Agreement) is entered into as of March 29, 2011 (Effective Date) by and between RADIUS HEALTH, INC., a Delaware corporation (Radius) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (NB) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.

Radius Health, Inc. – Clinical Trial Services Agreement* (May 23rd, 2011)

This Clinical Trial Services Agreement (this Agreement) is entered into as of March 29, 2011 (Effective Date) by and between RADIUS HEALTH, INC., a Delaware corporation (Radius) and NORDIC BIOSCIENCE CLINICAL DEVELOPMENT VII A/S, a Danish corporation (NB) that is a wholly-owned subsidiary of Nordic Bioscience Clinical Development A/S and sets forth the terms and conditions that will apply to the provision by NB to Radius of certain services.